Welcome to our dedicated page for Sinovac Biotech SEC filings (Ticker: SVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sinovac Biotech Ltd. filings document the company’s foreign private issuer reporting for a China-based vaccine developer, including Form 20-F annual reporting and Form 6-K current reports. The disclosures cover vaccine operations, consolidated financial statements, interim results, product portfolio context and pipeline categories such as combination vaccines, recombinant protein vaccines, mRNA technologies and antibodies.
Recent filings also record auditor engagement and annual-report correction matters, Nasdaq listing-compliance notices tied to filing deadlines, and board governance actions, including director independence, committee appointments and proceedings over board composition. These filings frame Sinovac’s capital-market reporting, governance controls and regulatory status as a Nasdaq issuer.
SINOVAC BIOTECH LTD executive Yang Guang (Helen), the Chief Business Officer, has filed an initial ownership report. The Form 3 shows she directly holds 172,900 common shares of the company. This filing records her existing stake as an insider and does not reflect a new purchase or sale.
SINOVAC BIOTECH LTD executive Gao Qiang, the Chief Operation Officer, has filed an initial ownership report showing direct holdings of 230,000 common shares. This Form 3 does not report any new purchase or sale, only the number of shares he beneficially owns after the reported holdings.
SINOVAC BIOTECH LTD Chief Financial Officer Wang Nan filed an initial ownership report showing holdings of 355,000 common shares. This Form 3 establishes Wang Nan’s existing direct ownership position in the company’s common equity and serves as a baseline for any future insider transactions.
SINOVAC BIOTECH LTD filed an initial insider ownership report for director WANG YU (NMN) on Form 3. This filing lists Wang as a director of the company but does not show any reported transactions or derivative positions in the provided data.
SINOVAC BIOTECH LTD director Jiao Shuge has filed an initial ownership report on Form 3. This filing identifies him as a director of the company and establishes his status as an insider. The filing does not report any share purchases, sales, or other transactions.
SINOVAC BIOTECH LTD director Lo Yuk Lam filed an initial statement of beneficial ownership on Form 3. The filing reports direct ownership of 90,000 common shares, par value $0.001 per share. This is a holdings report only and does not reflect any recent share purchase or sale.
SINOVAC BIOTECH LTD director Qiu Yu Min filed an initial Form 3, which is a required disclosure of insider status. This filing reports no transactions in the company’s securities and no derivative holdings, serving only to register Qiu Yu Min as a reporting insider.
SINOVAC BIOTECH LTD director Fu Shan filed an initial ownership report showing indirect holdings of 5,903,000 common shares. These shares are held by Vivo Capital Fund VIII, L.P., Vivo Capital Surplus Fund VIII, L.P. and Vivo Capital Fund IX, L.P., for which entities he serves as managing member of the general partners and may share voting and dispositive power with other members. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
SINOVAC BIOTECH LTD director Simon Anderson filed an initial ownership report showing he directly holds 70,000 common shares. This Form 3 does not record a new purchase or sale; it simply discloses his existing stake in the company’s common shares, par value $0.001 per share.
SINOVAC BIOTECH LTD director and Chief Executive Officer Weidong Yin filed an initial insider ownership report. The filing shows he directly holds 6,359,500 common shares of the company’s stock. This Form 3 reflects his position as a reporting insider rather than a new transaction.